(Q38373652)

English

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists (English)

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

0 references

0 references

author name string

Yunyun Yuan

1

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Orgil Elbegdorj

2

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Jianyang Chen

3

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Shashidhar K Akubathini

4

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Irina O Beletskaya

5

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Dana E Selley

6

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Yan Zhang

7

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

language of work or name

0 references

publication date

18 July 2011

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

Bioorganic & Medicinal Chemistry Letters

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

21

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

18

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

5625-5629

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Efficacy and tolerability of naltrexone in the management of alcohol dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Crystal structure of the ligand-free G-protein-coupled receptor opsin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Sustained-release naltrexone: novel treatment for opioid dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Pharmacological Properties of Bivalent Ligands Containing Butorphan Linked to Nalbuphine, Naltrexone, and Naloxone at μ, δ, and κ Opioid Receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Mu-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPgammaS binding assays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

6 September 2017

Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

14 September 2017

Effect of a mu-opioid receptor-selective antagonist on interleukin-6 fever

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

14 September 2017

The kappa-opioid receptor antagonist nor-BNI inhibits cocaine and amphetamine, but not cannabinoid (WIN 52212-2), abstinence-induced withdrawal in planarians: an instance of 'pharmacologic congruence'.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

23 June 2018

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

23 June 2018

Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

23 June 2018

Effects of the kappa opioid receptor antagonist MR-2266-BS on the acquisition of ethanol preference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

23 June 2018

ICI 174,864, a selective delta opioid antagonist, reverses the learning impairment produced by [leu]enkephalin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

23 June 2018

Modeling GPCR active state conformations: the β(2)-adrenergic receptor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

Kappa-opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

Attenuation of the discriminative stimulus properties of cocaine by delta-opioid receptor antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3171173

31 August 2018

The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics

1 reference

https://pubmed.ncbi.nlm.nih.gov/21788135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

N-Allylnoroxy-morphone: a new potent narcotic antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/21788135

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BMCL.2011.06.135

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38373652&oldid=1776868573"